July 2025 | Blood Cancers Today

July 2025

This issue of Blood Cancers Today includes a feature on hospital-community practice partnerships, a Get to Know interview with David Swoboda, MD, and more.

Features

In Focus

Collaboration in Cancer Care: Navigating Hospital-Community Practice Partnerships

Get to Know

Get to Know...David Swoboda, MD

Clinician's Corner

New Directions in First-Line Treatment for TP53-Mutated Mantle Cell Lymphoma

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: From Discovery to the Edge of Cure

GME Spotlight

Grand Rounds

The Delicate Balance of Immunotherapy and Immune Complications

News

Regulatory Actions

FDA ODAC: AQUILA Trial Supports Favorable Benefit-Risk of SQ Daratumumab in SMM

FDA ODAC: STARGLO Glofitamab DLBCL Trial Inapplicable for US Populations

News Roundup

Continuous Medicaid Coverage Associated With Lower Incidence of Stage IV Lymphoma Among Children and Young Adults

Study Finds ‘Significant’ Racial and Ethnic Disparities in Pregnancy Outcomes Among Women With Cancer

Meetings News: ASCO 2025

Blood Clot Risk Remains High for Patients With Newly Diagnosed Myeloma, Even With Aspirin Use

Do Blood Immune Biomarkers Predict Response to Mosunetuzumab for FL, MZL?

Epcoritamab Delivers 3-Year Remission in Tough LBCL Cases

Belantamab Linked to High Eye Toxicity in Patients With Myeloma, Study Finds

Meeting News: EHA 2025 Congress

ZUMA-3 Underscores Durable Survival Gains with Brexu-Cel in Relapsed B-Cell ALL

Talquetamab Still Works Well in Myeloma Patients, Even With Immune Response

Early Data Suggest DNA Damage Boost in R/R AML with Talazoparib Plus GO

Phase 3 IMROZ Trial Spotlights Isa-VRd Survival Benefit for Patients With Newly Diagnosed Myeloma

HemOnc Happenings

Eric Smith, MD, PhD, Receives Outstanding New Investigator Award from the American Society of Gene + Cell Therapy

July 2025